Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.
BACKGROUND
Estramustine phosphate sodium (EMP) frequently causes side-effects such as gastrointestinal discomfort, nausea, and edema in extremities. We analyzed single nucleotide polymorphisms (SNP) in the 17beta-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients.


METHODS
We performed genotyping of SNP in the HSD17B genes of 44 Japanese patients with newly diagnosed prostate cancer. The association of SNP and individual EMP side-effects was evaluated.


RESULTS
Peripheral edema occurred more frequently in patients with C/C genotype of IMS-JST123219 than in those with C/G genotype (OR: 5.47, 95% CI: 1.27-23.64). Haplotype analysis showed that appetite loss was associated with the G allele of IMS-JST123219 and the T allele of IMS-JST123218 (OR: 9.13, 95% CI: 1.15-72.76).


CONCLUSIONS
These preliminary data demonstrated that analyses of SNP in the HSD17B genes might predict the occurrence of side-effects from EMP.
Suzuki
Motofumi
M
Department of Urology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. SUZUKIM-URO@h.u-tokyo.ac.jp
Muto
Satoru
S
Hara
Kazuo
K
Ozeki
Takeshi
T
Yamada
Yasuhiko
Y
Kadowaki
Takashi
T
Tomita
Kyoichi
K
Kameyama
Shuji
S
Kitamura
Tadaichi
T
D015067:17-Hydroxysteroid Dehydrogenases / Q000235:genetics*; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D001066:Appetite / Q000187:drug effects; D004487:Edema / Q000139:chemically induced; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects*; D005787:Gene Frequency; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D012307:Risk Factors
D018931:Antineoplastic Agents, Hormonal; D004961:Estramustine; D015067:17-Hydroxysteroid Dehydrogenases